Baker McKenzie advised Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, in its registered direct offering of 25,925,925 shares of common stock at a purchase price of USD 1.35 per share, priced at-the-market under Nasdaq rules, resulting in net proceeds of USD 32.6 million, after deducting placement agents' fees but before expenses payable by the company.

Celsion intends to use the net proceeds for general corporate purposes, including research and development activities, capital expenditures, and working capital.

The Baker McKenzie team included Steven Canner, Carol Stubblefield, Eric Mattingly and Sarah Rosales.

Explore Our Newsroom